Novartis gets European Commission Approval for Afinitor to Treat Advanced Pancreatic Tumors

Swiss drug maker Novartis NVS received approval from the European Commission for use of Afinitor tablets to treat neuroendocrine tumors of pancreatic origin. Phase III trial data showed treatment with Afinitor more than doubled the time without tumor growth and reduced the risk of cancer progression by 65% when compared with placebo.